To evaluate the developmental outcomes and efficacy of early neurorehabilitation interventions in infants and toddlers born extremely preterm (<28 weeks gestation) with neurologic deficits related to prematurity-associated brain damage, such as intraventricular haemorrhage (IVH) or periventricular leukomalacia (PVL).This text will be in boldThis text will be in italicThis text will be in underlineThis text will be aligned to the centerThis text will be aligned to the rightThis text will be aligned to the LeftThis text will be aligned to the Justify - Infants born at <28 weeks gestation diagnosed with moderate to severe neurologic impairment due to documented brain injury on imaging within the neonatal intensive care unit (NICU) stay.Numeric Point 1Numeric Point 2Bullet Point 1Bullet Point 2Numeric Point 01Numeric Point 02Bullet Point o1Bullet Point o2Numeric Point iNumeric Point iiBullet Point box 1Bullet Point box 2Numeric Point INumeric Point IINext is Lower Case Alphabet - aLower Case Alphabet Point aLower Case Alphabet Point bNext is Upper Case Alphabet - ALower Case Alphabet Point ALower Case Alphabet Point BThis is a strikethrough textThis is a subscript textThis is a Superscript textLink for a text - Sample LinkIntended Text Line 1Intended Text Line 2Not Intended Text Line 1Not Intended Text Line 2

The primary objective is to assess the safety and tolerability of JS-001 in subjects with recurrent malignant lymphoma, and to evaluate its preliminary efficacy.The secondary objectives are to: 1) characterize the single-dose and multi-dose pharmacokinetic (PK) profile of JS-001, 2) characterize the immunogenicity of JS-001; 3) assess the dose-efficacy relationship of JS-001 single agent, and 4) preliminarily evaluate biomarkers associated with the efficacy of JS-001.